Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Beta-secretase 1 (BACE1) is a transmembrane aspartic protease that initiates the production of amyloid-beta peptides by cleaving amyloid precursor protein (APP). This cleavage is a critical step in the pathogenesis of Alzheimer's disease. BACE1 also plays a role in myelination, particularly in peripheral nerves. It is considered a therapeutic target for Alzheimer's disease, with inhibitors aimed at reducing amyloid-beta production.
Inhibition of BACE1 prevents the formation of amyloid-beta peptides.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Beta-secretase 1 (BACE1).